HANSOH PHARMACEUTICAL GROUP COMPANY LIMITED

Balance Sheet Hansoh Pharmaceutical Group Company Limited

Stocks

3692

KYG549581067

Pharmaceuticals

Market Closed - Hong Kong S.E. Other stock markets 09:08:11 17/07/2026 BST			5-day change	1st Jan Change
31.80 ^HKD	-4.10%		+2.05%	-11.86%

07-14	Avery Therapeutics, Inc. announced that it has received $320 million in funding from a group of investors	CI
07-13	Avere Therapeutics, Inc. announced that it expects to receive $69 million in funding from a group of investors	CI

d3ed9b1790b7a621e64260d33ecde2.XbxNom43Qwhyw8MK9AOHb5PZtm2oQmdoj1jA3VDAm1U.Dt0CyS9tMCUigZxSgXWwGKuG3Cf3NBIw6mquvwe0riQo-BfOXVgIewS3rA

Published financial data: HANSOH PHARMACEUTICAL GROUP COMPANY LIMITED

Annual

Quarterly

Halfyear

YTD

LTM

Fiscal Period: December	2021	2022	2023	2024	2025
Revenues	9.94B	9.38B	10.1B	12.26B	15.03B
Total Revenues	9.94B	9.38B	10.1B	12.26B	15.03B
Cost of Goods Sold, Total	870M	870M	1.03B	1.12B	1.52B
Gross Profit	9.06B	8.51B	9.07B	11.14B	13.51B
Selling General & Admin Expenses, Total	4.37B	4.15B	4.24B	4.51B	4.74B
R&D Expenses	1.8B	1.69B	2.1B	2.7B	3.36B
Other Operating Expenses	-	63.73M	53.9M	31.98M	14.3M
Other Operating Expenses, Total	6.17B	5.9B	6.39B	7.24B	8.11B
Operating Income	2.9B	2.61B	2.68B	3.9B	5.4B
Interest Expense, Total	-52.82M	-58.14M	-66.68M	-6.69M	-3.16M
Interest And Investment Income	254M	332M	1.02B	1.05B	1.1B
Net Interest Expenses	201M	273M	953M	1.04B	1.09B
Income (Loss) On Equity Invest.	-	-13.86M	-2.12M	-	-
Currency Exchange Gains (Loss)	-9.31M	44.56M	4.57M	21.43M	-44.06M
Other Non Operating Income (Expenses)	63.43M	117M	105M	87.35M	111M
EBT, Excl. Unusual Items	3.15B	3.03B	3.74B	5.05B	6.56B
Gain (Loss) On Sale Of Investments	144M	-91.54M	158M	61.27M	-16.71M
Gain (Loss) On Sale Of Assets	3.94M	11.24M	2.1M	5.72M	4.3M
Asset Writedown	-	-	-	-31.98M	-
Other Unusual Items	-	-	-135M	-	-
EBT, Incl. Unusual Items	3.3B	2.95B	3.77B	5.09B	6.55B
Income Tax Expense	587M	365M	489M	713M	995M
Earnings From Continuing Operations	2.71B	2.58B	3.28B	4.37B	5.56B
Net Income to Company	2.71B	2.58B	3.28B	4.37B	5.56B
Net Income - (IS)	2.71B	2.58B	3.28B	4.37B	5.56B
Net Income to Common Incl Extra Items	2.71B	2.58B	3.28B	4.37B	5.56B
Net Income to Common Excl. Extra Items	2.71B	2.58B	3.28B	4.37B	5.56B
Per Share Items
Net EPS - Basic	0.46	0.44	0.55	0.74	0.93
Basic EPS - Continuing Operations	0.46	0.44	0.55	0.74	0.93
Basic Weighted Average Shares Outstanding	5.92B	5.92B	5.92B	5.93B	5.96B
Net EPS - Diluted	0.44	0.44	0.52	0.73	0.93
Diluted EPS - Continuing Operations	0.44	0.44	0.52	0.73	0.93
Diluted Weighted Average Shares Outstanding	6B	5.93B	6.02B	5.95B	5.98B
Normalized Basic EPS	0.33	0.32	0.39	0.53	0.69
Normalized Diluted EPS	0.33	0.32	0.39	0.53	0.69
Dividend Per Share	0.07	0.09	0.19	0.32	0.39
Payout Ratio	14.04	27.56	19.9	42.51	36.22
American Depositary Receipts Ratio (ADR)	5	5	5	5	5
Supplemental Items
EBITDA	3.15B	2.93B	3.02B	4.28B	5.76B
EBITA	2.9B	2.62B	2.69B	3.92B	5.41B
EBIT	2.9B	2.61B	2.68B	3.9B	5.4B
EBITDAR	3.18B	2.94B	3.03B	4.28B	5.77B
Effective Tax Rate - (Ratio)	17.79	12.37	12.97	14.03	15.19
Total Current Taxes	442M	281M	584M	768M	1.12B
Total Deferred Taxes	145M	83.91M	-95.64M	-54.83M	-128M
Normalized Net Income	1.97B	1.89B	2.34B	3.16B	4.1B
Interest on Long-Term Debt	3.26M	58.14M	60.91M	3.48M	3.16M
Supplemental Operating Expense Items
Marketing Expenses	-	-	-	-	-
Selling and Marketing Expenses	3.43B	3.55B	3.53B	3.8B	4.06B
General and Administrative Expenses	943M	597M	710M	713M	672M
Research And Development Expense From Footnotes	1.8B	1.69B	2.1B	2.7B	3.36B
Net Rental Expense, Total	29.42M	8.65M	5.46M	4.51M	4.68M
Imputed Operating Lease Interest Expense	6.34M	981K	671K	109K	1.06M
Imputed Operating Lease Depreciation	23.08M	7.67M	4.79M	4.4M	3.62M
Stock-Based Comp., Other (Total)	65.47M	179M	171M	138M	143M
Total Stock-Based Compensation	65.47M	179M	171M	138M	143M

Fiscal Period: December	2021	2022	2023	2024	2025
Assets
Cash And Equivalents	14.7B	17.62B	22.43B	22.62B	31.55B
Short Term Investments	1.88B	1.47B	1.94B	780M	8.23M
Trading Asset Securities, Total	2.36B	2.54B	512M	17.24M	17.61M
Total Cash And Short Term Investments	18.94B	21.63B	24.88B	23.42B	31.57B
Accounts Receivable, Total	3.68B	3.58B	3.21B	3.17B	3.06B
Other Receivables	106M	47.42M	80.89M	94.27M	186M
Total Receivables	3.78B	3.63B	3.3B	3.26B	3.25B
Inventory	410M	448M	576M	651M	609M
Prepaid Expenses	969K	1.73M	3.83M	883K	1.37M
Other Current Assets, Total	44.88M	126M	125M	106M	124M
Total Current Assets	23.18B	25.83B	28.88B	27.44B	35.56B
Gross Property Plant And Equipment	4.84B	5.09B	5.24B	5.5B	5.75B
Accumulated Depreciation	-1.36B	-1.64B	-1.96B	-2.25B	-2.57B
Net Property Plant And Equipment	3.48B	3.45B	3.28B	3.25B	3.18B
Long-term Investments	395M	654M	685M	702M	772M
Other Intangibles, Total	17.04M	33.42M	177M	245M	363M
Other Long-Term Assets, Total	93.4M	33.29M	13.93M	21.32M	30.53M
Total Assets	27.16B	30B	33.04B	31.66B	39.9B
Liabilities
Accounts Payable, Total	248M	222M	164M	218M	334M
Accrued Expenses, Total	2.2B	1.92B	1.97B	2.09B	2.16B
Current Portion of Long-Term Debt	-	-	4.18B	40.87M	40.5M
Current Portion of Leases	9.97M	15.54M	16.09M	16.01M	16.97M
Current Income Taxes Payable	134M	90.94M	85.65M	46.67M	259M
Unearned Revenue Current, Total	22.2M	25.1M	38.47M	19.23M	1.18B
Other Current Liabilities	408M	341M	406M	265M	402M
Total Current Liabilities	3.02B	2.62B	6.86B	2.7B	4.39B
Long-Term Debt	3.74B	4.28B	39.74M	-	-
Long-Term Leases	74.92M	79.57M	64.71M	61.01M	47.62M
Deferred Tax Liability Non Current	267M	351M	255M	200M	72.3M
Other Non Current Liabilities	22.93M	22.46M	21.99M	21.52M	21.04M
Total Liabilities	7.13B	7.35B	7.24B	2.98B	4.54B
Common Stock, Total	52K	52K	52K	52K	53K
Additional Paid In Capital	14.02B	13.93B	14.1B	14B	17.88B
Retained Earnings	6.91B	8.78B	11.4B	13.92B	17.46B
Treasury Stock	-57.97M	-28.03M	-109M	-13.22M	-2.88M
Comprehensive Income and Other	-847M	-36.91M	403M	775M	26.58M
Total Common Equity	20.03B	22.65B	25.79B	28.68B	35.36B
Total Equity	20.03B	22.65B	25.79B	28.68B	35.36B
Total Liabilities And Equity	27.16B	30B	33.04B	31.66B	39.9B
Supplemental Items
ECS Total Shares Outstanding on Filing Date	5.92B	5.92B	5.92B	5.93B	6.05B
ECS Total Common Shares Outstanding	5.92B	5.92B	5.92B	5.93B	6.05B
Book Value / Share	3.38	3.83	4.35	4.83	5.84
Tangible Book Value	20.01B	22.61B	25.62B	28.43B	35B
Tangible Book Value Per Share	3.38	3.82	4.32	4.79	5.78
Total Debt	3.83B	4.38B	4.3B	118M	105M
Net Debt	-15.11B	-17.25B	-20.58B	-23.3B	-31.47B
Debt Equivalent Oper. Leases	235M	69.21M	43.66M	36.06M	37.42M
Equity Method Investments, Total	-	241M	-	-	-
Account Code - Inventory Valuation	6	6	6	6	5
Inventories - Raw Materials, Total	95.19M	105M	138M	157M	219M
Inventories - Work In Process, Total	212M	230M	288M	282M	198M
Inventories - Finished Goods, Total	103M	113M	150M	212M	192M
Buildings, Total	2.28B	2.31B	2.32B	2.48B	2.47B
Machinery, Total	1.79B	2.13B	2.27B	2.36B	2.58B
Full Time Employees	12.15K	10.52K	9.12K	8.99K	9.35K
Accumulated Allowance for Doubtful Accounts (Supple)	1.07M	8.22M	30.6M	12.42M	11.59M

Fiscal Period: December	2021	2022	2023	2024	2025
Net Income	2.71B	2.58B	3.28B	4.37B	5.56B
Depreciation & Amortization - CF	272M	336M	356M	388M	380M
Amortization of Goodwill and Intangible Assets - (CF)	-	8.83M	10.76M	13.24M	11.64M
Depreciation & Amortization, Total	272M	345M	366M	401M	391M
Amortization of Deferred Charges, Total - (CF)	6.26M	-	-	-	1.7M
(Gain) Loss From Sale Of Asset	-3.94M	-11.24M	-2.1M	-5.72M	-4.3M
(Gain) Loss on Sale of Investments - (CF)	-26.28M	-67.58M	-158M	-61.27M	16.71M
Asset Writedown & Restructuring Costs	-	-	-	31.98M	-
(Income) Loss On Equity Investments - (CF)	-	13.86M	2.12M	-	-
Stock-Based Compensation (CF)	65.47M	179M	171M	138M	143M
Provision and Write-off of Bad Debts	817K	7.15M	22.38M	-18.18M	-831K
Other Operating Activities, Total	-22M	-2.96M	-820M	-1.03B	-913M
Change In Accounts Receivable	-549M	90.45M	342M	62.67M	110M
Change In Inventories	-112M	-40.94M	-130M	-86.73M	20.93M
Change In Accounts Payable	124M	-26.03M	-58.53M	54.09M	116M
Change in Unearned Revenues	-173M	2.9M	13.37M	-19.24M	1.16B
Change in Other Net Operating Assets	282M	-332M	90.17M	25.38M	138M
Cash from Operations	2.58B	2.74B	3.12B	3.86B	6.74B
Capital Expenditure	-460M	-273M	-220M	-222M	-356M
Sale of Property, Plant, and Equipment	54.77M	21.1M	10.96M	23.96M	27.26M
Sale (Purchase) of Intangible assets	-15.16M	-19M	-143M	-303M	-133M
Investment in Marketable and Equity Securities, Total	-2.1B	-5.85B	648M	-1.99B	-7.9B
Other Investing Activities, Total	257M	181M	778M	1.1B	1.21B
Cash from Investing	-2.26B	-5.94B	1.07B	-1.39B	-7.15B
Short Term Debt Issued, Total	-	-	900M	500M	-
Long-Term Debt Issued, Total	3.85B	-	-	-	-
Total Debt Issued	3.85B	-	900M	500M	-
Short Term Debt Repaid, Total	-	-	-900M	-500M	-
Long-Term Debt Repaid, Total	-12.29M	-42.48M	-18.96M	-4.2B	-22.38M
Total Debt Repaid	-12.29M	-42.48M	-919M	-4.7B	-22.38M
Issuance of Common Stock	15.11M	13.14M	37.99M	33.19M	3.59B
Repurchase of Common Stock	-57.97M	-76.62M	-115M	-33.69M	-
Common Dividends Paid	-381M	-712M	-652M	-1.86B	-2.01B
Common & Preferred Stock Dividends Paid	-381M	-712M	-652M	-1.86B	-2.01B
Other Financing Activities, Total	-	-	-5.77M	-3.21M	-
Cash from Financing	3.42B	-818M	-754M	-6.07B	1.55B
Foreign Exchange Rate Adjustments	-79.29M	-40.56M	-122M	-62.43M	-51.58M
Net Change in Cash	3.66B	-4.05B	3.31B	-3.66B	1.09B
Supplemental Items
Cash Interest Paid	-	-	5.77M	3.21M	-
Cash Income Tax Paid (Refund)	319M	324M	590M	807M	911M
Levered Free Cash Flow	1.3B	1.45B	2.07B	2.4B	5.16B
Unlevered Free Cash Flow	1.34B	1.49B	2.11B	2.4B	5.16B
Change In Net Working Capital	343M	373M	-261M	48.2M	-1.74B
Net Debt Issued / Repaid	3.84B	-42.48M	-18.96M	-4.2B	-22.38M

Fiscal Period: December	2021	2022	2023	2024	2025
Profitability
Return on Assets	7.55	5.7	5.31	7.54	9.44
Return on Total Capital	8.66	6.41	5.86	8.28	10.51
Return On Equity %	14.31	12.11	13.53	16.05	17.35
Return on Common Equity	14.31	12.11	13.53	16.05	17.35
Margin Analysis
Gross Profit Margin %	91.24	90.73	89.78	90.89	89.89
SG&A Margin	44	44.21	41.97	36.77	31.51
EBITDA Margin %	31.74	31.25	29.94	34.89	38.35
EBITA Margin %	29.15	27.89	26.62	31.93	36.02
EBIT Margin %	29.15	27.79	26.52	31.83	35.94
Income From Continuing Operations Margin %	27.31	27.54	32.44	35.66	36.97
Net Income Margin %	27.31	27.54	32.44	35.66	36.97
Net Avail. For Common Margin %	27.31	27.54	32.44	35.66	36.97
Normalized Net Income Margin	19.83	20.18	23.14	25.74	27.29
Levered Free Cash Flow Margin	13.12	15.48	20.48	19.58	34.35
Unlevered Free Cash Flow Margin	13.45	15.87	20.89	19.61	34.36
Asset Turnover
Asset Turnover	0.41	0.33	0.32	0.38	0.42
Fixed Assets Turnover	3.44	2.71	3	3.76	4.68
Receivables Turnover (Average Receivables)	2.92	2.59	2.97	3.84	4.82
Inventory Turnover (Average Inventory)	2.46	2.03	2.02	1.82	2.41
Short Term Liquidity
Current Ratio	7.67	9.86	4.21	10.18	8.09
Quick Ratio	7.52	9.64	4.11	9.9	7.92
Operating Cash Flow to Current Liabilities	0.85	1.05	0.45	1.43	1.53
Days Sales Outstanding (Average Receivables)	124.97	141.11	122.69	95.29	75.66
Days Outstanding Inventory (Average Inventory)	148.63	179.95	180.94	201.08	151.38
Average Days Payable Outstanding	69.28	94.6	60.72	58.58	68.23
Cash Conversion Cycle (Average Days)	204.32	226.46	242.91	237.78	158.81
Long Term Solvency
Total Debt/Equity	19.11	19.33	16.68	0.41	0.3
Total Debt / Total Capital	16.05	16.2	14.3	0.41	0.3
LT Debt/Equity	19.06	19.26	0.4	0.21	0.13
Long-Term Debt / Total Capital	16	16.14	0.35	0.21	0.13
Total Liabilities / Total Assets	26.26	24.51	21.93	9.41	11.37
EBIT / Interest Expense	54.84	44.85	40.18	583.36	1.71K
EBITDA / Interest Expense	59.99	50.77	45.68	643.36	1.83K
(EBITDA - Capex) / Interest Expense	51.28	46.08	42.38	610.18	1.72K
Total Debt / EBITDA	1.21	1.48	1.41	0.03	0.02
Net Debt / EBITDA	-4.77	-5.84	-6.76	-5.41	-5.43
Total Debt / (EBITDA - Capex)	1.41	1.63	1.52	0.03	0.02
Net Debt / (EBITDA - Capex)	-5.58	-6.44	-7.28	-5.71	-5.79
Growth Over Prior Year
Total Revenues, 1 Yr. Growth %	14.33	-5.56	7.69	21.35	22.57
Gross Profit, 1 Yr. Growth %	14.94	-6.1	6.57	22.85	21.22
EBITDA, 1 Yr. Growth %	5.5	-4.93	3.18	41.41	34.75
EBITA, 1 Yr. Growth %	4.46	-7.45	2.82	45.55	38.25
EBIT, 1 Yr. Growth %	4.46	-7.56	2.76	45.64	38.42
Earnings From Cont. Operations, 1 Yr. Growth %	5.61	-4.76	26.85	33.39	27.07
Net Income, 1 Yr. Growth %	5.61	-4.76	26.85	33.39	27.07
Normalized Net Income, 1 Yr. Growth %	4.73	-3.9	23.5	35.01	29.96
Diluted EPS Before Extra, 1 Yr. Growth %	1.21	-1.29	19.65	40.62	26.42
Accounts Receivable, 1 Yr. Growth %	17.54	-2.66	-10.18	-1.38	-3.45
Inventory, 1 Yr. Growth %	37.29	9.21	28.55	13.1	-6.5
Net Property, Plant and Equip., 1 Yr. Growth %	50.85	-0.73	-4.93	-0.99	-2.09
Total Assets, 1 Yr. Growth %	30.63	10.46	10.12	-4.18	26.04
Tangible Book Value, 1 Yr. Growth %	12.01	13	13.28	11	23.1
Common Equity, 1 Yr. Growth %	12.05	13.07	13.9	11.18	23.31
Cash From Operations, 1 Yr. Growth %	7.81	6.37	13.69	23.93	74.46
Capital Expenditures, 1 Yr. Growth %	-67.78	-40.7	-19.51	1.08	60.58
Levered Free Cash Flow, 1 Yr. Growth %	-135.47	15.68	42.45	16.01	115.01
Unlevered Free Cash Flow, 1 Yr. Growth %	-136.38	15.53	41.77	13.92	114.72
Dividend Per Share, 1 Yr. Growth %	12.44	20.84	118.47	63.53	22.73
Compound Annual Growth Rate Over Two Years
Total Revenues, 2 Yr. CAGR %	6.97	3.91	0.85	14.31	21.96
Gross Profit, 2 Yr. CAGR %	6.81	3.89	0.04	14.42	22.03
EBITDA, 2 Yr. CAGR %	3.15	-0.96	-0.96	20.79	38.04
EBITA, 2 Yr. CAGR %	2.07	-2.86	-2.45	22.33	41.85
EBIT, 2 Yr. CAGR %	2.07	-3.03	-2.54	22.33	41.98
Earnings From Cont. Operations, 2 Yr. CAGR %	3.01	0.29	9.91	30.08	30.19
Net Income, 2 Yr. CAGR %	3.01	0.29	9.91	30.08	30.19
Normalized Net Income, 2 Yr. CAGR %	2.86	0.32	8.94	29.13	32.46
Diluted EPS Before Extra, 2 Yr. CAGR %	-2.64	-0.05	8.68	29.71	33.33
Accounts Receivable, 2 Yr. CAGR %	27.93	6.97	-6.49	-5.88	-2.42
Inventory, 2 Yr. CAGR %	-0.51	22.45	18.49	20.58	2.84
Net Property, Plant and Equip., 2 Yr. CAGR %	34.26	22.37	-2.86	-2.98	-1.54
Total Assets, 2 Yr. CAGR %	17.79	20.12	10.29	2.72	9.89
Tangible Book Value, 2 Yr. CAGR %	23.88	12.51	13.14	12.13	16.89
Common Equity, 2 Yr. CAGR %	23.91	12.56	13.48	12.53	17.09
Cash From Operations, 2 Yr. CAGR %	-12.02	7.08	9.97	18.7	47.04
Capital Expenditures, 2 Yr. CAGR %	-11.88	-56.29	-30.91	-9.8	27.4
Levered Free Cash Flow, 2 Yr. CAGR %	-38.21	-37.12	28.37	28.55	57.94
Unlevered Free Cash Flow, 2 Yr. CAGR %	-37.43	-36.33	27.98	27.09	56.4
Dividend Per Share, 2 Yr. CAGR %	-	16.57	62.48	89.01	41.67
Compound Annual Growth Rate Over Three Years
Total Revenues, 3 Yr. CAGR %	8.76	2.62	5.15	7.26	17
Gross Profit, 3 Yr. CAGR %	8.39	2.32	4.77	7.13	16.64
EBITDA, 3 Yr. CAGR %	9.72	-0.36	0.4	11.52	25.27
EBITA, 3 Yr. CAGR %	8.96	-2.01	-1.01	11.47	27.42
EBIT, 3 Yr. CAGR %	8.96	-2.12	-1.14	11.43	27.48
Earnings From Cont. Operations, 3 Yr. CAGR %	12.55	0.35	8.46	17.24	29.07
Net Income, 3 Yr. CAGR %	12.55	0.35	8.46	17.24	29.07
Normalized Net Income, 3 Yr. CAGR %	11.42	0.55	7.52	17.02	29.4
Diluted EPS Before Extra, 3 Yr. CAGR %	5.15	-2.19	6.13	18.43	28.61
Accounts Receivable, 3 Yr. CAGR %	11.59	16.8	0.92	-4.82	-5.08
Inventory, 3 Yr. CAGR %	-5.09	2.63	24.45	16.66	10.78
Net Property, Plant and Equip., 3 Yr. CAGR %	35.99	21.41	12.49	-2.24	-2.69
Total Assets, 3 Yr. CAGR %	47.79	15.3	16.69	5.24	9.97
Tangible Book Value, 3 Yr. CAGR %	101.19	20.14	12.76	12.42	15.68
Common Equity, 3 Yr. CAGR %	100.96	20.19	13	12.71	16.02
Cash From Operations, 3 Yr. CAGR %	7.54	-6.28	9.24	14.44	34.96
Capital Expenditures, 3 Yr. CAGR %	6.45	-22.78	-46.42	-21.57	9.32
Levered Free Cash Flow, 3 Yr. CAGR %	-30.84	-24.78	-17.42	24.11	52.6
Unlevered Free Cash Flow, 3 Yr. CAGR %	-30.26	-24.16	-16.86	23.11	51.36
Dividend Per Share, 3 Yr. CAGR %	-	-	43.72	62.83	63.67
Compound Annual Growth Rate Over Five Years
Total Revenues, 5 Yr. CAGR %	12.83	8.69	5.52	7.15	11.58
Gross Profit, 5 Yr. CAGR %	12.48	8.24	4.97	7	11.36
EBITDA, 5 Yr. CAGR %	11.48	8.3	4.85	7.61	14.03
EBITA, 5 Yr. CAGR %	11.03	7.33	3.74	7.09	14.31
EBIT, 5 Yr. CAGR %	11.03	7.26	3.66	7.01	14.26
Earnings From Cont. Operations, 5 Yr. CAGR %	12.95	10.12	11.49	11.33	16.68
Net Income, 5 Yr. CAGR %	12.95	10.12	11.49	11.33	16.68
Normalized Net Income, 5 Yr. CAGR %	11.9	9.5	10.42	11.13	16.88
Diluted EPS Before Extra, 5 Yr. CAGR %	-	-	6.55	9.5	16.27
Accounts Receivable, 5 Yr. CAGR %	16.36	10.29	3.97	7.13	-0.43
Inventory, 5 Yr. CAGR %	3.04	0.39	3.72	9.46	15.31
Net Property, Plant and Equip., 5 Yr. CAGR %	27.09	24.11	18.87	10.99	6.65
Total Assets, 5 Yr. CAGR %	41.31	38.56	31.46	10.09	13.92
Tangible Book Value, 5 Yr. CAGR %	46.47	38.05	59.81	16.87	14.4
Common Equity, 5 Yr. CAGR %	46.44	38.04	59.9	17.07	14.62
Cash From Operations, 5 Yr. CAGR %	15.63	14.35	8.5	3.01	23.03
Capital Expenditures, 5 Yr. CAGR %	14	1.25	-10.45	-17.83	-24.23
Levered Free Cash Flow, 5 Yr. CAGR %	-	62.75	-12.08	-6.8	7.04
Unlevered Free Cash Flow, 5 Yr. CAGR %	-	63.56	-11.73	-6.76	7.05
Dividend Per Share, 5 Yr. CAGR %	-	-	-	-	42.89